• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Mahony Susan

    6/9/25 4:05:19 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mahony Susan

    (Last) (First) (Middle)
    C/O ASSEMBLY BIOSCIENCES, INC.
    TWO TOWER PLACE, 7TH FLOOR

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ASSEMBLY BIOSCIENCES, INC. [ ASMB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $15.81 06/05/2025 A 3,500 (1) 06/05/2035 Common Stock 3,500 $0 3,500 D
    Explanation of Responses:
    1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders.
    /s/ John O. Gunderson, as Attorney-in-Fact 06/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ASMB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/31/24 4:24:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/23/24 8:26:39 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/26/24 9:15:02 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

      – Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b portion of the Phase 1a/b study of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor

      6/30/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

      – Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following delivery and review of option data package – SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovativ

      6/25/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/eve

      5/27/25 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/17/25 4:05:04 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Houghton Michael

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/9/25 4:05:21 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mahony Susan

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/9/25 4:05:19 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Assembly Biosciences with a new price target

      Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

      3/25/25 8:26:24 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences upgraded by Jefferies with a new price target

      Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously

      9/20/24 7:32:14 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Assembly Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50

      9/13/21 6:42:05 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    SEC Filings

    See more
    • Assembly Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      6/25/25 4:05:30 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      6/9/25 5:00:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Assembly Biosciences Inc.

      10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      5/8/25 4:15:34 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    See more
    • Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

      -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

      11/8/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

      −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

      2/15/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Assembly Biosciences Inc.

      SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      11/14/24 3:22:29 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/24/24 4:28:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/20/24 8:35:37 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care